Leonid Timashev
Stock Analyst at RBC Capital
(3.38)
# 1,005
Out of 4,996 analysts
108
Total ratings
52.58%
Success rate
2.59%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Upgrades: Outperform | $42 → $44 | $27.89 | +57.76% | 4 | Sep 26, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $36 → $38 | $26.83 | +41.63% | 2 | Sep 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $145 → $151 | $127.00 | +18.90% | 1 | Aug 28, 2025 | |
| XNCR Xencor | Maintains: Outperform | $32 → $15 | $11.57 | +29.65% | 1 | Aug 21, 2025 | |
| INSM Insmed | Maintains: Outperform | $120 → $138 | $137.03 | +0.71% | 5 | Aug 13, 2025 | |
| LEGN Legend Biotech | Maintains: Outperform | $75 → $77 | $33.37 | +130.75% | 13 | Aug 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $12 → $13 | $8.89 | +46.23% | 2 | Aug 8, 2025 | |
| NUVB Nuvation Bio | Maintains: Outperform | $6 → $7 | $3.20 | +118.75% | 2 | Aug 8, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $48 → $49 | $16.05 | +205.30% | 14 | Aug 8, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Outperform | $38 → $39 | $28.50 | +36.84% | 7 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $349 → $364 | $326.06 | +11.64% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $184 → $189 | $116.76 | +61.87% | 13 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $50 → $45 | $39.04 | +15.27% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $25 | $7.40 | +238.07% | 1 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $53 | $37.54 | +41.18% | 1 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 → $17 | $11.30 | +50.44% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $3.65 | +36.99% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $16 | $3.40 | +370.59% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $54 → $21 | $15.00 | +40.00% | 12 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $80 | $50.40 | +58.73% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.14 | +273.83% | 6 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $1.56 | +92.31% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $82.70 | -15.36% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $18 | $5.80 | +210.34% | 4 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $6.56 | -39.02% | 8 | Aug 6, 2024 |
Alkermes
Sep 26, 2025
Upgrades: Outperform
Price Target: $42 → $44
Current: $27.89
Upside: +57.76%
IDEAYA Biosciences
Sep 9, 2025
Maintains: Outperform
Price Target: $36 → $38
Current: $26.83
Upside: +41.63%
Jazz Pharmaceuticals
Aug 28, 2025
Maintains: Outperform
Price Target: $145 → $151
Current: $127.00
Upside: +18.90%
Xencor
Aug 21, 2025
Maintains: Outperform
Price Target: $32 → $15
Current: $11.57
Upside: +29.65%
Insmed
Aug 13, 2025
Maintains: Outperform
Price Target: $120 → $138
Current: $137.03
Upside: +0.71%
Legend Biotech
Aug 12, 2025
Maintains: Outperform
Price Target: $75 → $77
Current: $33.37
Upside: +130.75%
Verastem
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $8.89
Upside: +46.23%
Nuvation Bio
Aug 8, 2025
Maintains: Outperform
Price Target: $6 → $7
Current: $3.20
Upside: +118.75%
Edgewise Therapeutics
Aug 8, 2025
Maintains: Outperform
Price Target: $48 → $49
Current: $16.05
Upside: +205.30%
NewAmsterdam Pharma Company
Aug 7, 2025
Maintains: Outperform
Price Target: $38 → $39
Current: $28.50
Upside: +36.84%
Aug 7, 2025
Maintains: Outperform
Price Target: $349 → $364
Current: $326.06
Upside: +11.64%
Aug 5, 2025
Maintains: Outperform
Price Target: $184 → $189
Current: $116.76
Upside: +61.87%
Jul 29, 2025
Maintains: Sector Perform
Price Target: $50 → $45
Current: $39.04
Upside: +15.27%
Jul 17, 2025
Maintains: Outperform
Price Target: $32 → $25
Current: $7.40
Upside: +238.07%
Jul 16, 2025
Maintains: Outperform
Price Target: $68 → $53
Current: $37.54
Upside: +41.18%
Jun 20, 2025
Reiterates: Outperform
Price Target: $13 → $17
Current: $11.30
Upside: +50.44%
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $3.65
Upside: +36.99%
Jun 3, 2025
Maintains: Outperform
Price Target: $15 → $16
Current: $3.40
Upside: +370.59%
May 19, 2025
Downgrades: Sector Perform
Price Target: $54 → $21
Current: $15.00
Upside: +40.00%
May 7, 2025
Maintains: Outperform
Price Target: $82 → $80
Current: $50.40
Upside: +58.73%
Mar 19, 2025
Reiterates: Outperform
Price Target: $8
Current: $2.14
Upside: +273.83%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $1.56
Upside: +92.31%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $82.70
Upside: -15.36%
Jan 15, 2025
Reiterates: Outperform
Price Target: $18
Current: $5.80
Upside: +210.34%
Aug 6, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $6.56
Upside: -39.02%